Top Links

Articles Related to Pharmacology

Potential COVID-19 Therapeutics: A Perspective on Pharmacological Properties and Safety

There are no guidelines for pharmacological treatment of COVID-19 disease, but several drugs are being tested every day in search of an optimal therapeutic strategy. The drugs that have been tested, so far, include some antiviral drugs such as danoprevir, favipiravir, darunavir, nelfinavir, remdesivir, umifenovir and the combination lopinavir/ritonavir. Others are drugs targeting inflammatory mediators such as meplazumab, siltuximab, tocilizumab, azithromycin and corticosteroids. Also included in this array of tested drugs are those with pleiotropic actions against SARS-CoV-2 infection like chloroquine/hydroxychloroquine, ivermectin and nitazoxanide, postulated as inhibitors of several phases of virus life cycle. Upon diagnosis of SARS-CoV-2 infection, it is pertinent to embark on a treatment approach based on potential antiviral options, adequately managed under proper medical situation. We suggest that, in addition to the antiviral option efforts, drugs targeting inflammatory mediators should be considered.
View complete article: PDF  |  Full-text

How Nurse Education Impacts Her Career?

A great proportion of healthcare services need high-quality medication and nursery. For high-quality nursery needs best nurses and their education. Gradually, different types of nursery education systems can impact their life and career. In the future, more parameters can be used for judging the quality and promotion of nurses. This editorial addresses different educational efforts for their progresses in medical knowledge promotion, technical capability improvement and salary promotion.
View complete article: PDF  |  Full-text

Charles Bonnet Syndrome: Rapid Resolution of Visual Hallucinations with Low Dose Risperidone

Charles Bonnet syndrome (CBS) comprises of complex visual hallucinations secondary to visual impairment in the presence of preserved cognition. Age related macular degeneration and other factors causing visual deterioration lead to visual hallucinations in 10-15% of patients. Sensory deprivation and social isolation are risk factors for development of CBS. The distressing hallucinations are underreported by patients and to date there are no robust evidence based guidelines to manage these hallucinations. Since visual hallucinations are associated with multiple psychiatric disorders as well, these patients are often referred to mental health providers. Here, we present the case of CBS development after macular degeneration. Rapid and sustained resolution of visual hallucinations and associated distress was observed with low dose Risperidone.
View complete article: PDF  |  Full-text

The Dose and its Acute Toxicology: A Systematic Review Article in the First Phase of Experimental Pharmacology

Hundreds and thousands of acute toxicity studies are conducted in experimental pharmacology with assumption hypothesis every year. It is usually concluded with inadequately validated data during the period of investigation within 24 hours.
View complete article: PDF  |  Full-text

Veterinary Considerations for the Theoretical Resurrection of Extinct Species

The de-extinction of the dinosaur is a dubious possibility but its consideration brings forth some issues that are at least worthy of scientific discussion. In this review, we discuss two distinct issues that have implications for a de-extinct species such as a dinosaur: the ability, or lack thereof, to safely sedate a rare and potentially fractious animal capable of harming the veterinary staff tasked with its care; and, disease risks associated with a species that has been extinct for millions of years. To identify potential sedatives, comparative pharmacology will be needed to uncover the links between receptor pharmacology and the desired clinical outcomes of activating established alpha-2 adrenergic, opioid, and benzodiazepine receptors. Specific to disease control, it will be necessary to understand the unique susceptibility of the new species to current diseases as well as predicting their reservoir capacity for potential human and veterinary pandemic diseases. While the topics presented herein are not exhaustive, this review highlights some of the foremost research that should be conducted in order to serve the unique veterinary needs of a de-extinct species using the dinosaur as a paradigm. Addressing these issues should be considered if an intact dinosaur genome becomes available, regardless of the feasibility of dinosaur resurrection.
View complete article: PDF  |  Full-text

Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery

Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
View complete article: PDF  |  Full-text

Treatments for Atopic Dermatitis

Atopic dermatitis, also known as eczema, affects about 10-20% of children in the UK and about 1-3% of adults [1]. The incidence of atopic dermatitis has increased as much as 3 fold in the past 40 years
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to Pharmacology

Marc Poirot

Research Director at INSERM
Cancer Research Center of Toulouse
University of Toulouse
France

Burton M. Altura

Professor
Department of Medicine
Suny downstate medical center
United States

Jean-François Desaphy

Associate Professor
Department of Pharmacy & Drug Sciences
University of Bari
Italy

Yu Huang

Professor
School of Biomedical Sciences
Chinese University of Hong Kong
Hong Kong

Eric Fung

Professor of Pharmacology
Department of Oral Biology
University of Nebraska Medical Center College of Dentistry
United States

Nikolai N. Modyanov

Professor
Department of Physiology and Pharmacology
The University of Toledo College of Medicine
United States

David J. MacEwan

Professor
Department of Molecular & Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
United Kingdom

Salim A. Hamadi

Professor
Department of Pharmacology and Biomedical Sciences
Petra University
Jordan

CHARLES C. MUSCOPLAT

Professor
Department of Food Science and Nutrition
University of Minnesota
United States

Yan Zhou

Associate Professor
Department of Pharmacology
Guangxi Medical University
China
Submit Manuscript